Corporate Social Responsibility Report

Overview

The report presents Henlius's first CSR disclosure and highlights the company's launch of HLX01 as China's first approved biosimilar in 2019. It reports that more than 7,000 patients had benefited from the product by year-end. The report also highlights a 2019 investment of RMB4,280,192 in charity and public-welfare programs.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2019
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services